DRUG-RESISTANCE IN ACUTE-LEUKEMIA

[1] Von Kalken C.K., Pinedo H.M., Giaccone G., Multidrug resistance from the clinical point of view, Eur. J. Cancer, 27, pp. 1481-1486, (1991)

[2] Zwelling L.A., Hinds M., Chan D., Mayes J., Sie K.L., Parker E., Silberman L., Radcliff A., Beran M., Blick M., Characterization of an amsacrine-resistant line of human leukemia cells, J. Biol. Chem., 264, pp. 16411-16420, (1989)

[3] Owens J.K., Shewach D.S., Ullman B., Mitchell B.S., Resistance to 1–beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the de-oxycytidine kinase gene, Cancer Res., 52, pp. 2389-2393, (1992)

[4] Antonsson B.E., Avramis V.I., Nyce J., Holcenberg J.S., Effect of 5–azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/O and CCRF/CEM/ dCK-1, Cancer Res., 47, pp. 3672-3678, (1987)

[5] Fridland A., Verhoef V., Mechanism for Ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process, Semin. Oncol., 14, pp. 262-268, (1987)

[6] Rosman M., Lee M.H., Creasey W.A., Sartorelli A.C., Mechanisms of resistance to 6–Thiopurines in human leukemia, Cancer Res., 34, pp. 1952-1956, (1974)

[7] Sobrero A.F., Bertino J.R., Clinical aspects of drug resistance, Cancer Surveys, 5, pp. 93-107, (1986)

[8] Kalman T.J., Polyglutamylation of folates and anti-folates as a target of chemotherapy, Pharmacology and Therapeutics. Suppl. 1990, Molecular Aspects of Chemotherapy, pp. 139-297, (1990)

[9] Galivan J., Johnson T., Rhee M., McGuire J., Priest D., Vasevan V., The role of folylpolyglutamate syn-thetase and γ-glutamyl hydrolase in altering cellular foly- and antifolylpolyglutarnates, Adv. Enzyme Regul., 26, pp. 147-155, (1987)

[10] Lin J.T., Tong W.P., Trippett T.M., Niedzwiecki D., Tao Y., Tan C., Steinherz P., Schweitzer B.I., Bertino J.R., Basis for natural resistance to methotrexate in human acute nonlymphoblastic leukemia, Leukemia Res., 15, pp. 1191-1196, (1991)

[1] Von Kalken C.K., Pinedo H.M., Giaccone G., Multidrug resistance from the clinical point of view, Eur. J. Cancer, 27, pp. 1481-1486, (1991)

[2] Zwelling L.A., Hinds M., Chan D., Mayes J., Sie K.L., Parker E., Silberman L., Radcliff A., Beran M., Blick M., Characterization of an amsacrine-resistant line of human leukemia cells, J. Biol. Chem., 264, pp. 16411-16420, (1989)

[3] Owens J.K., Shewach D.S., Ullman B., Mitchell B.S., Resistance to 1–beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the de-oxycytidine kinase gene, Cancer Res., 52, pp. 2389-2393, (1992)

[4] Antonsson B.E., Avramis V.I., Nyce J., Holcenberg J.S., Effect of 5–azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/O and CCRF/CEM/ dCK-1, Cancer Res., 47, pp. 3672-3678, (1987)

[5] Fridland A., Verhoef V., Mechanism for Ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process, Semin. Oncol., 14, pp. 262-268, (1987)

[6] Rosman M., Lee M.H., Creasey W.A., Sartorelli A.C., Mechanisms of resistance to 6–Thiopurines in human leukemia, Cancer Res., 34, pp. 1952-1956, (1974)

[7] Sobrero A.F., Bertino J.R., Clinical aspects of drug resistance, Cancer Surveys, 5, pp. 93-107, (1986)

[8] Kalman T.J., Polyglutamylation of folates and anti-folates as a target of chemotherapy, Pharmacology and Therapeutics. Suppl. 1990, Molecular Aspects of Chemotherapy, pp. 139-297, (1990)

[9] Galivan J., Johnson T., Rhee M., McGuire J., Priest D., Vasevan V., The role of folylpolyglutamate syn-thetase and γ-glutamyl hydrolase in altering cellular foly- and antifolylpolyglutarnates, Adv. Enzyme Regul., 26, pp. 147-155, (1987)

[10] Lin J.T., Tong W.P., Trippett T.M., Niedzwiecki D., Tao Y., Tan C., Steinherz P., Schweitzer B.I., Bertino J.R., Basis for natural resistance to methotrexate in human acute nonlymphoblastic leukemia, Leukemia Res., 15, pp. 1191-1196, (1991)